Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GH Research PLC GHRS

Healthcare
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product... see more

Recent & Breaking News (NDAQ:GHRS)

    GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

    GlobeNewswire 15 hours ago

    GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

    GlobeNewswire September 3, 2024

    GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

    GlobeNewswire September 3, 2024

    GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

    GlobeNewswire May 3, 2024

    GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

    GlobeNewswire February 29, 2024

    GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

    GlobeNewswire January 18, 2024

    GH Research Reports Third Quarter Financial Results and Provides Business Updates

    GlobeNewswire November 9, 2023

    GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

    GlobeNewswire September 29, 2023

    GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

    GlobeNewswire August 23, 2023

    GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

    GlobeNewswire May 11, 2023

    GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

    GlobeNewswire March 2, 2023

    GH Research Provides Business Updates and Highlights Key Upcoming Milestones

    GlobeNewswire January 9, 2023

    GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

    GlobeNewswire November 10, 2022

    GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

    GlobeNewswire August 23, 2022

    GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

    GlobeNewswire May 18, 2022

    GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

    GlobeNewswire March 28, 2022

    GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

    GlobeNewswire December 6, 2021

    GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression

    GlobeNewswire December 6, 2021

    GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

    GlobeNewswire September 23, 2021